CCSVI 2013: ‘debunking,’ spin, and legal drama

Anne Kingston on the MS research that captured headlines in 2013

CCSVI death knell sounds again

Scanning study finds narrowed veins common, CCSVI rare


Shorter CCSVI explainer: Time to liberate liberation treatment

Last week’s shut-down of the Albany, NY clinical trial investigating CCSVI treatment due to lack of patient enrollment is a big set-back on a number of fronts. It’s bad news for the Saskatchewan government, which allocated $2.2 million and recruited patients to travel to the U.S.—and a  blow for those who’d taken part in the trial or were lined up to go. But, like all failures, it’s instructive.

Time to liberate ‘liberation’ therapy from MS

Anne Kingston explains why we’ve reached the WTF moment in CCSVI research

Debunking the latest study ‘debunking’ CCSVI

On the quest for clarity on MS theory


Tory senators kill proposed legislation on controversial MS treatment

OTTAWA – The Conservatives have used their Senate majority to kill legislation that would have authorized a national strategy to deal with a controversial therapy for multiple sclerosis.

Beyond Dr. Google: How social media can improve our health

The third in a series on the credibility of health information on the Web


Controversial MS treatment will be tested in B.C. and Quebec

TORONTO – The federal government is going ahead with a patient trial of a controversial experimental treatment for multiple sclerosis.

The medical politics blocking CCSVI trials

A defeated private member’s bill shows how pitched the battle has become

Saskatchewan goes rogue on CCSVI clinical trials

Brad Wall: ‘It’s a good day in the province of Saskatchewan’

Hurry up and wait for a CCSVI strategy

MS drugs get fast-tracked all the time. Why can’t a clinical trial get the same treatment?

Liberation therapy: the ‘wave of complications’ breaks

Zamboni’s research almost certainly has to have been junk